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SEVENTEEN AMINO ACID PEPTIDE 
(PEPTIDE P) FOR TREATING ISCHEMIA 
AND REPERFUSION INJURY 
This application is a divisional of application Ser. No. 
10/003,328 ?led Dec. 6, 2001, now US. Pat. No. 6,544,950. 
FIELD OF THE INVENTION 
The invention relates to the use of a novel seventeen 
amino acid peptide to treat cerebral ischemia and ischemic 
heart disease including reperfusion injury. 
BACKGROUND 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction With possible irreversible organ dam 
age. Cerebral ischemia results from decreased blood and 
oxygen ?oW implicating one or more of the blood vessels of 
the brain. In cerebral ischemia, the individual suffers a stroke 
With sudden development of a focal neurologic de?cit and, 
in most cases, some degree of brain damage. The decreased 
blood How may be due to, for example, an occlusion such as 
a thrombus or embolus, vessel rupture, sudden fall in blood 
pressure, change in the vessel lumen diameter due to 
atherosclerosis, trauma, aneurysm, developmental 
malformation, altered permeability of the vessel Wall or 
increased viscosity or other quality of the blood. Decreased 
blood How may also be due to failure of the systemic 
circulation and severe prolonged hypotension. Ischemic 
necrosis of the spinal cord may result in sensory or motor 
symptoms or both that can be referred to cervical, thoracic 
or lumbar levels of the spine. Ischemic heart disease results 
from an imbalance betWeen myocardial oxygen supply and 
demand. In ischemic heart disease, the individual suffers 
angina pectoris, acute myocardial infarction or sudden 
death. The imbalance may be caused by, for example, 
atherosclerotic obstruction of one or more large coronary 
arteries, nonatheromatous coronary obstructive lesions such 
as embolism, coronary ostial stenosis associated With luetic 
aortitis, coronary artery spasm, congenital abnormalities of 
the coronary circulation, increased myocardial oxygen 
demands exceeding the normal supply capabilities as in 
severe myocardial hypertrophy, reduction in the oxygen 
carrying capacity of the blood such as n anemia, or as a 
consequence of inadequate cardiac perfusion pressure due to 
hypotension from any cause. US. Pat. No. 6,294,579 B1 
discloses methods for treating ischemia by administering 
certain Deltorphin peptides. The publication by LaZarus et 
al., “Environmental Health Perspectives”, Vol. 102, No. 4, 
pages 648—654 (1994), discloses naturally occurring opiod 
peptides. 
Current treatments for ischemia encompass behavioral 
changes drug therapy, and/or surgical intervention. Drugs 
are frequently preferred before resorting to invasive proce 
dures and to provide more immediate relief than long-term 
behavioral changes. Thus, there is a need for a therapeutic 
agent Which can be useful in treating or preventing ischemia. 
SUMMARY OF THE INVENTION 
It is an object of the invention to provide a novel peptide 
and use of that peptide to treat ischemia. 
The present invention meets the object by providing a 
novel seventeen amino acid peptide (Peptide P) Which is 
useful for treating cerebral ischemia and ischemic heart 
disease. Also provided is a method of treating ischemia in a 
mammal comprised administering a pharmaceutically effec 
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tive amount of Peptide P to said mammal. The ischemic 
tissue may be brain, spinal cord or heart. 
The present invention is also directed to a method of 
reducing the effect of an ischemic episode comprised of 
administering an effective amount of pharmaceutically 
effective amount of Peptide P to said mammal. 
The present invention is also directed to a method of 
treating cerebral or spinal cord ischemia or ischemic heart 
disease in a mammal comprised of administering an effec 
tive amount of pharmaceutically effective amount of Peptide 
P to said mammal. 
Preferably, Peptide P is administered as a pharmaceutical 
composition at a dosage in the range of about 0.5 mg/kg 
body Weight to about 20 mg/kg body Weight, or alternatively 
loWer doses in the range of about 1 mg/kg body Weight to 
about 1000 mg/kg body Weight of the mammal. Preferably, 
the mammal is human. 
BRIEF DESCRIPTION OF THE DRAWING 
The sole ?gure accompanying the application is a graph 
shoWing the effect of Peptide-P on infarct volume folloWing 
cerebral ischemia. Peptide-P at a concentration of 4 mg/Kg 
Was injected (IV) 1 hr after occlusion of the external carotid 
artery (ECA). Controls Were injected With 100 pl of physi 
ological saline. Ischemic volume Was assessed after 24 hrs 
of reperfusion. Treated animals shoWed a decrease in infarct 
volume, p<0.006 compared to saline controls. Control had 
infarct siZe of 34.45+/—3.6% and Peptide-P had 16.87+/— 
3.3%. 
DESCRIPTION OF THE INVENTION 
Peptide P is a linear 17 amino acid peptide Which has been 
synthesiZed on a commercial peptide synthesiZer such as the 
type available from Applied Biosystem. Peptide P has the 
amino acid sequence Tyr-D-Ala-Phe-Ala-Asp-Val-Ala-Ser 
Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 and a MW of 
1860.1 With alanine as D-isomer. The peptide P can be 
produced by a number of methods, such as by use of an 
automated peptide synthesiZer, through recombinant 
molecular biology techniques, or isolated from a naturally 
occurring source. 
Peptide P can be administered to ameliorate or inhibit 
damage caused by a stroke. A stroke is the acute neurologic 
injury caused by one of several pathologic processes involv 
ing the blood vessels of the brain. The pathologic process 
may be intrinsic to the vessel itself such as in 
arteriosclerosis, or may originate from a remote location 
such as an embolus, or may result from decreased perfusion 
or increased blood viscosity With inadequate cerebral blood 
?oW, or may result from the rupture of a vessel in the 
subarachnoid space or intracerebral tissue. 
The main causes of ischemic stroke are thrombosis, 
vasoconstriction and embolism. Diagnosis of a stroke can be 
readily made by one of ordinary skill in the art. Signs of 
stroke include paralysis, slurred speech, general confusion, 
impairment of gait, cortical sensory loss over toes, foot and 
leg and urinary incontinence, to name just a feW. The 
diagnosis can be con?rmed by cerebral angiography and by 
a computed axial tomography (CT) scan of the brain. 
If a stroke occurs, Peptide P can be administered to limit 
injury to the brain. The ideal mode of administration is by 
intravenous (IV) or intraperitoneal (I.P.) injection at a dose 
of about 0.5—20 mg/kg, or alternatively, loWer doses of about 
1—1000 mg/kg. Peptide P can also be administered by 
subcutaneous or intraarterial injection into the carotid artery, 
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or by direct injection into the brain, e.g., intracerebroven 
tricular injection (ICV) for dispersion into other areas. 
Very often a stroke is caused by a cerebral embolism, the 
likelihood of Which can frequently be predicted. In these 
cases, the Peptide P can be administered prophylactically to 
prevent or lessen the amount of brain tissue injured during 
such an event. Many types of heart disease including cardiac 
arrhythmias or diseases due to cardiac structural abnormali 
ties may produce cerebral emboli. Atrial ?brillation from 
any cause, including rheumatic valvular disease, may result 
in emboli being produced Which can migrate into the arteries 
of the brain. Emboli formation and migration can occur as 
a result of arteriosclerotic cardiovascular disease and myo 
cardial infarction. Emboli formation and migration can 
occur as a result of arteriosclerotic cardiovascular disease 
and myocardial infarction. Emboli formation is also a de? 
nite risk for intracardiac surgery and prosthetic valve 
replacement. Heart bypass surgery and angioplasty can 
result in the formation of microemboli, Which can migrate 
into the arteries of the brain and cause a series of occlusions 
in a number or arteries, resulting in mental impairment. 
Cerebral embolism is also the principal complication in the 
transplant of arti?cial hearts. Furthermore, the overall risk of 
stroke after any type of general surgery is 0.2 to 1 percent. 
The vegetations of acute and subacute bacterial endocarditis 
can give rise to emboli, Which can occlude a major intrac 
ranial artery. Thus, When these disease states or surgical 
procedures are planned or are happening, Peptide P can be 
administered to prevent brain damage due to any resultant 
emboli and stroke. 
Peptide P can be administered to ameliorate or prevent 
ischemic necrosis of the spinal cord. The ischemia may be 
caused by an endarteritis of surface arteries leading to 
thrombosis. Atherosclerotic thrombosis of the aorta or dis 
secting aortic aneurysms may cause infarction of the spinal 
cord (myelomalacia) by occluding nutrient arteries at 
cervical, thoracic or lumbar levels, as can paralysis during 
cardiac surgery requiring clamping of the aorta for more 
than 30 minutes and aortic arteriography. Infarctive or 
hemorrhagic vascular lesions of the spinal cord 
(hematomyelia) may result in the sudden onset of symptoms 
referable to sensory or motor or both spinal tract lesions. 
Peptide P can also be administered to ameliorate or inhibit 
damage caused by ischemic heart disease. Ischemic heart 
disease is a general term for a spectrum of diseases of 
diverse etiology caused by an imbalance betWeen oXygen 
supply and demand. The usual cause of the imbalance is 
atherosclerotic obstruction of large coronary arteries, lead 
ing to an absolute decrease in coronary artery blood ?oW. An 
imbalance may also result from nonatheromatous coronary 
obstructive lesions such as embolism, coronary ostial steno 
sis associated With luetic aortitis, coronary artery spasm, or 
very uncommonly an arteritis of the coronary vessels. The 
imbalance may also be due to congenital abnormalities of 
the coronary circulation, an increase in myocardial oXygen 
demands exceeding the supply capabilities in a normal 
coronary circulation, a diminished oxygen-carrying capacity 
of the blood such as in anemia or in the presence of 
carboXyhemoglobin (e. g., due to cigarette or cigar smoking), 
or as a consequence of inadequate perfusion pressure due to 
hypotension. When ischemic events are transient, they may 
be associated With angina pectoris: if prolonged, they can 
lead to myocardial necrosis and scarring With or Without the 
clinical picture of acute myocardial infarction. Ischemic 
heart disease may be readily diagnosed by one skilled in the 
art. There may be predictive changes in the 
electrocardiogram, since ischemia alters electrical properties 
of the heart. Such changes include inversion of the T Wave 
and displacement of the ST segment. Another important 
consequence of myocardial ischemia is electrical instability 
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leading to ventricular tachycardia or ventricular ?brillation. 
Stress tests and coronary arteriography may also provide 
diagnostic information. These diagnostic test results may 
determine the need for Peptide P administration. 
Since ischemic heart disease is usually asymptomatic 
until the eXtent of coronary artery blockage is Well 
advanced, preventative measures to control risk factors and 
life style patterns associated With the disease are also 
recommended. In patients in the symptomatic phase of the 
disease, meticulous attention to life patterns or risk factors 
must be given in an attempt to promote lesion regression or 
at least prevent progression. Risk factors include a positive 
family history of ischemic heart disease, diabetes, 
hyperlipidemia, hypertension, obesity and cigarette smok 
ing. Life patterns include sedentary lifestyle, psychosocial 
tension and certain personality traits. 
Peptide P may be administered to asymptomatic individu 
als having one or more risk factors and/or life style patterns 
or to individuals already in the symptomatic phase of 
ischemic heart disease to reduce or prevent disease progres 
sion. Additionally, Peptide P may be administered to the 
folloWing patients: those having careers that involve the 
safety of others (e.g., commercial airline pilots) and that 
present With questionable symptoms, suspicious or positive 
noninvasive test results, and in Whom there are reasonable 
doubts about the state of the coronary arteries; males Who 
are 45 or older and females Who are 55 Will undergo valve 
replacement and Who may or may not have clinical evidence 
of myocardial ischemia; and those at high risk after myo 
cardial infarction because of the recurrence of angina, heart 
failure, frequent ventricular premature contractions, or signs 
of ischemia in the stress test, to name just a feW. Peptide P 
may be administered either separately or in combination 
With other cardiac drugs such as nitrates, beta-adrenergic 
blockers, calcium channel antagonists and/or aspirin and 
either separately or in combination With ?brinolytic drugs 
such as tissue plasminogen activator (tPA), streptokinase 
and urokinase. Use of Peptide P may prolong life and/or 
reduce or eliminate the need for invasive procedures such as 
coronary arteriography and coronary artery bypass grafting. 
According to the present invention, Peptide P is admin 
istered to a mammal to treat cerebral or spinal cord ischemia 
or ischemic heart disease including reperfusion injury. Pep 
tide P may be formulated for administration in an aqueous 
based liquid such as phosphate buffered saline to form an 
emulsion, or it may be formulated in an organic liquid such 
as cyclodeXtrin or dimethylsulfoXide to form a solution. The 
peptide-P active ingredient should be present in an effective 
amount of about 0.001 Wt. % up to 25.0 Wt. % in such 
compositions. The solution or emulsion may be adminis 
tered by any route, but it is preferably administered parenter 
ally such as by intravenous, intramuscular, intradermal or 
intraperitoneal injections. 
A preferred Peptide P dose is in the range of about 0.5 
mg/kg body Weight of the mammal to about 20 mg/kg body 
Weight of the mammal, or alternatively loWer doses of about 
1 mg/kg body Weight of the mammal to about 1000 mg/kg 
body Weight of the mammal. The time of administration of 
a single dose of Peptide P is preferably up to about four 
hours after onset of an ischemic episode. HoWever, Peptide 
P may be administered concurrently With the onset of a 
ischemic episode or even prior to onset of ischemia and still 
produce a therapeutic effect. 
Ef?cacy of Peptide P treatment may be evaluated using 
noninvasive clinical imaging methods such as magnetic 
resonance imaging (MRI) of the affected region to determine 
the siZe of the damaged area. In cerebral ischemia, it is also 
possible to assess neurologic de?cit by performance on 
behavioral tests such as cognitive recognition or memory 
function such as the National Institutes of Health (NIH) 
stroke scale. 
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While the speci?c mechanism of Peptide P action on 
ischemia is unknown, Peptide P exhibits a speci?c and 
reproducible effect on decreasing neurological de?cit and 
cerebral infarct volume. This invention Will be further 
appreciated in light of the folloWing example. 
The folloWing example is presented to illustrate the 
invention but the invention is not considered to be limited 
thereto. 
EXAMPLE 
A murine model of ischemia/reperfusion injury Was used 
to evaluate the effects of Peptide P on cerebral blood ?oW, 
behavioral changes and ischemia infarct volume. 
Induction of Ischemia 
Ischemia Was induced by transient occlusion of the exter 
nal carotid artery (ECA). Male ICR mice Weighing about 
30—35 g Were anesthetiZed With an intraperitoneal (i.p.) 
injection of chloral hydrate (350 mg/kg of body Weight) and 
xylaZine (4 mg/kg of body Weight). Rectal temperatures 
Were maintained at 3710.5° C. With a heating pad and 
incubator. The left femoral artery Was cannulated With a 
PE-10 catheter for measurement of arterial blood pressure, 
pO2, pCO2 and pH. 
A midline incision Was made in the skin of the neck and 
the left common carotid artery (LCCA) Was exposed. The 
ECA, superior thyroid artery (STA) and occipital artery 
(OA) Were isolated. The STA and OA Were electrocoagu 
lated using a cautery probe (Baster Hi Temp Cautery, Baxter 
Healthcare Corp.) and divided. The base of the ECA Was 
secured With a microsurgical clip, then the distal end of the 
ECA Was ligated With a 6-0 nylon suture and the ECA Was 
cut. A blunted 5-0 blue mono?lament nylon suture Was 
placed in the end of the ECA, the surgical clip Was removed, 
then the blunted suture Was advanced into the ECA until 
resistance Was detected. The blunted suture Was then tight 
ened to prevent both slipping of the internal suture and 
bleeding. The suture Was trimmed and the incision Was 
sealed by suturing the skin. The suture remained in place for 
varying lengths of time up to 24 h. At the desired time, 
reperfusion of the brain (restoration of blood How to the 
brain) Was accomplished by retreating the suture from the 
ECA. 
Mean arterial blood pressure (MABP), pO2, pCO2 and 
pH Were measured before occlusion, 10 min after occlusion 
and 30 min after reperfusion. Cerebral blood How Was 
monitored by laser-Doppler ?oWmetry With a ?ber optic 
probe placed 2 mm posterior and 6 mm lateral to the bregma 
on the ipsilateral hemisphere of the brain. 
Treatment 
The test compound Was Peptide P (Tyr-D-Ala-Phe-Ala 
Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile 
NH2). For analysis of the test compound, a solution of the 
test compound in saline or 1% cyclodextrin Was prepared. 
The test compound in solution Was administered by I.V. 
injection at multiple doses prior to or up to 4 hours folloWing 
ischemic injury. 
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Control animals (n=5) received I.V. injections of saline or 
1% cyclodextrin. Peptide P treated animals (n=6) received 4 
mg/kg of Peptide P 1 hour folloWing middle cerebral antery 
occlusion (MCAO). At time O, animals Were subjected to 1 
hour focal middle cerebral arterial occlusion (MCAO) 
ischemia and 24 hour of reperfusion. Cerebral blood Was 
assessed by laser-Doppler ?oWmetry With a ?ber optic probe 
prior to ischemia and at 0.5 hour, 1 hour and 2 hours post 
ischemia. Ischemic volume Was measured and animals Were 
assessed for behavior changes using a numerical ranking 
from 0 to 3 according to the folloWing criteria: 0=no 
observable de?cits (normal); 1=failure to extend right fore 
paW upon lifting by the tail (mild); 2=circling to the con 
tralateral side (moderate); and 3=leaning to the contralateral 
side at rest or no spontaneous motor activity (severe). 
Evaluation of Treatment 
Brain infarct volume Was measured after 1 hour of 
ischemia and again at 24 hours after reperfusion. At the 
desired endpoint, the animal Was euthaniZed. The brain Was 
immediately removed and placed into a mouse brain matrix 
(ASI, Warren, Mich.) and 2 mm sections Were made. Brain 
sections Were stained With 2% 2,3,5-triphenyltetraZolium 
chloride (TTC). Infarct siZe Was determined according to the 
formula: 
(Contralateral volume-ipsilateral undamaged volume)><100/Con— 
tralateral volume 
to eliminate the effects of edema. Quantitation of contralat 
eral and ipsilateral volumes Was determined by image analy 
sis using a Scion Image (NIH Image Version 1.59) modi?ed 
by Scion Corp. and Adobe Photoshop 2.0.1. 
Statistical analysis of the volume analysis results Was 
performed using the Student’s t-test or analysis of variance 
(ANOVA) folloWed by the Bonferroni test. Statistical sig 
ni?cance Was assigned to comparisons of sections from 
control versus Peptide P treated animals With p<0.006. Data 
Were expressed as mean1standard error of the mean (SEM). 
Prior to Peptide P treatment, there Were no signi?cant 
differences in MABP, pO2, pCO2, pH or rectal temperature 
betWeen control animals and deltorphin-treated animals. 
Upon induction of ischemia by middle cerebral arterial 
occlusion, both control and Peptide P-treated animals had a 
25% reduction in cerebral blood ?oW Which Was sustained 
for 1 hour during the ischemia. After cessation of ischemia, 
cerebral blood ?oW returned to baseline levels Within 0.5 
hour. Post ischemia, there Were no signi?cant differences in 
MABP, pO2, pCO2, pH or rectal temperature betWeen 
control animals and deltophin-treated animals. There Was, 
hoWever, a signi?cant (<0.05) decrease in neurological 
de?cits from Peptide P treated animals (0.44111) versus 
control animals (1.5510.19). Additionally, infarct volume 
Was also signi?cantly reduced by 59% in Peptide P-treated 
animals (2414.8 mm3) compared to control animals (5817.2 
mm3) after 24 h of reperfusion, see FIG. 1, Table 1 & 2. 
TABLE 1 
Mouse strain/C57 
Peptide-P (Pep-P) 
Pep-P Pep-P Pep-P Pep-P Pep-P Pep-P Total Average 
No. 
Sex 
Ischemia Time 
Reperfusion Time 
Cross Section Area 1 
Cross Section Area 2 
1 2 3 4 5 6 
M M M M M M 
1hr 1hr 1hr 1hr 1hr 1hr 
24 hr 24 hr 24 hr 24 hr 24 hr 24 hr 
10.43 9.53 10.74 13.46 11.00 11.71 
17.91 16.64 17.44 19.06 18.11 18.8 
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TABLE l-continued 
Peptide-P (Pep-P) 
Mouse strain/C57 Pep-P Pep-P Pep-P Pep-P Pep-P Pep-P Total Average 
Cross Section Area 3 19.77 19.62 19.46 20.7 21.19 21.3 
Cross Section Area 4 20.43 18.93 19.26 19.73 20.85 20.73 
Total Cross Section Area 68.54 64.72 66.9 72.95 71.15 72.54 416.8 68.77 1 1.4% 
Damaged Cross Section Area 1 3.69 0 1.42 1.89 0 0.27 
Damaged Cross Section Area 2 5.66 0.32 1.38 3.27 4.59 1.8 
Damaged Cross Section Area 3 6.47 1.12 2.63 7.23 2.22 5.15 
Damaged Cross Section Area 4 1.84 1.11 3.06 5.54 6.11 4.46 
Damaged Cross Section Area 17.66 2.55 8.49 17.93 12.92 11.68 71.23 11.87 1 2.4% 
Damaged % 25.77 3.94 12.69 24.58 18.16 16.10 101.24 16.87 1 3.3% 
Corrected Volume 35.32 5.10 16.98 35.86 25.84 23.36 142.46 23.74 1 4.8% mm3 
Corrected Volume (mm3) = Damaged Cross Section Area x 2 mm section 
After 1 hr ischemia mice Were injected With 100 #1 Peptide-P (4 mg/Kg) 
TABLE 2 
Saline 
Mouse strain/C57 Saline Saline Saline Saline Saline Total Average 
No. 1 2 3 4 5 
Sex M M M M M 
Ischemia Time 1 hr 1 hr 1 hr 1 hr 1 hr 
Reperfusion Time 24 hr 24 hr 24 hr 24 hr 24 hr 
Cross Section Area 1 14.81 14.65 12.55 13.18 15.35 
Cross Section Area 2 22.52 22.39 19.52 20.68 22.08 
Cross Section Area 3 25.24 25.45 21.84 23.51 24.77 
Cross Section Area 4 24.51 24.05 21.54 24.98 23.81 
Total Cross Section Area 87.08 86.54 75.45 82.35 86.01 417.43 83.49 1 2.2% 
Damaged Cross Section Area 1 6.58 4.49 1.77 1.02 4.83 
Damaged Cross Section Area 2 9.7 6.86 2.42 2.21 8.81 
Damaged Cross Section Area 3 11.86 10.7 7.65 5.79 9.52 
Damaged Cross Section Area 4 10.02 12.22 9.03 11.21 8.26 
Damaged Cross Section Area 38.16 34.27 20.87 20.23 31.42 144.95 28.99 1 3.6% 
Damaged % 43.82 39.60 27.66 24.57 36.53 172.18 34.45 + 3.6% 
Corrected Volume 76.32 68.54 41.74 40.46 62.84 289.9 57.98 1 7.2% mm3 
Corrected Volume (mm3) = Damaged Cross Section Area x 2 mm section 
After 1 hr ischemia mice Were injected With 100 #1 physiological saline 
Identi?cation of a novel seventeen amino acid Peptide, 
Peptide P and a method for treating cerebral or spinal cord 
ischemia or ischemic heart disease including reperfusion 
injury by Peptide P administration is thus disclosed. Peptide 
P, SEQ ID NO:1 is formulated for biocompatible adminis 
tration in a preferred dose in the range of about 0.5—20 
mg/kg, or alternatively 1—1000 mg/kg body Weight of the 
animal. The Peptide P dose may be administered up to four 
hours after the onset of an ischemic attack. Alternatively, the 
Peptide P dose may be administered prophylactically in 
patients at risk for an ischemic attack such as, for example, 
prior to surgery. Peptide P administration reduces the effect 
of an ischemic event. 
It should be understood that the embodiments of the 
present invention shoWn and described in the speci?cation 
are only preferred embodiments of the inventors Who are 
skilled in the art and thus are not limiting in any Way. 
Therefore various changes, modi?cations or alterations to 
these embodiments may be made or restored to Without 
departing from the spirit of the invention and scope of the 
folloWing claims. 
What is claimed is: 
1. Amethod of treating ischemia in a mammal comprising 
administering an effective amount of Peptide P SEQ ID NO: 
1, in a pharmaceutically acceptable carrier. 
2. The method of claim 1 Wherein said Peptide P is 
administered prior to onset of ischemia. 
3. The method of claim 1, Wherein said Peptide P is 
administered 24 hours prior to the onset of ischemia. 
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4. The method of claim 1, Wherein said Peptide P is 
administered up to four hours subsequent to onset of 
ischemia. 
5. The method of claim 1, Wherein said Peptide P is 
administered substantially concurrently With onset of 
ischemia. 
6. The method of claim 1, Wherein said Peptide P is 
administered in a carrier formulation selected from the 
group consisting of a solution, an emulsion and a suspen 
sion. 
7. The method of claim 1, Wherein said Peptide P is 
administered parenterally. 
8. The method of claim 1, Wherein said Peptide P is 
administered at a concentration in the range of about 0.5—20 
mg/kg of body Weight of said mammal. 
9. The method of claim 1, Wherein said Peptide P is 
administered at a concentration in the range of 1—1000 
mg/kg of body Weight of said mammal. 
10. The method of claim 1, Wherein said Peptide P is 
administered to treat cerebral ischemia. 
11. The method of claim 1, Wherein said Peptide P is 
administered to treat ischemic heart disease and/or reperfu 
sion injury. 
12. The method of claim 1, Wherein said Peptide P is 
administered to treat spinal cord ischemia. 
13. A method for treating cerebral ischemia in a mammal 
comprising administering a pharmaceutically effective con 
centration of a Peptide P, SEQ ID NO: 1. 
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14. A method of reducing effects of an ischemic episode 17. The method of claim 13, Wherein the said Peptide P is 
in a mammal comprising administering a pharmaceutically administered substantially concurrently With onset of 
effective concentration of a Peptide P, SEQ ID NO: 1. ischemia_ 
15. The method of 14, Wherein said Peptide P is admin 
istered up to four hour subsequent to said ischemic episode. 5 
16. The method of claim 14, Wherein said Peptide P is 
administered prior to said ischemic episode. * * * * * 
